NMPA Accepted New Drug Application for DBPR108

NHRI announced that the National Medical Products Administration (NMPA) in China had accepted the New Drug Application (NDA) for DBPR108, an oral drug for the treatment of diabetes, on April 28th, 2023.

About DBPR108

DBPR108 (prusogliptin) is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, as an add-on therapy in patients with type 2 diabetes (T2D) that is inadequately controlled with metformin.

About IBPR of the NHRI

Institute of Biotechnology and Pharmaceutical Research of the NHRI is a mission-driven drug discovery and development engine with vertical and horizontal coordination and integration. For more information, please visit https://ibpr.nhri.org.tw/en/ .

Share Button

Comments are closed.